References
- McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007;92:F424–F427.
- El-Khuffash A, Barry D, Walsh K, et al. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch Dis Child Fetal Neonatal Ed. 2008;93:F407–F412.
- Koch J, Hensley G, Roy L, et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117:1113–1121.
- Richards J, Johnson A, Fox G, et al. second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics. 2009;124:e287–e293.
- Rennie JM, Doyle J, Cooke RW. Early administration of indomethacin to preterm infants. Arch Dis Child. 1986;61:233–238.
- Coombs RC, Morgan ME, Durbin GM, et al. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child. 1990;65:1067–1071.
- Laudignon N, Chemtob S, Bard H, et al. Effect of indomethacin on cerebral blood flow velocity of premature newborns. Biol Neonate. 1988;54:254–262.
- Narayanan M, Cooper B, Weiss H, et al. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr. 2000;136:330–337.
- Gonzalez A, Sosenko IR, Chandar J, et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr. 1996;128:470–478.
- Keller RL, Clyman RI. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics. 2003;112:583–587.
- International Committee for the Classification of Retinopathy of, P. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991–999.
- Kliegman RM. Neonatal necrotizing enterocolitis: implications for an infectious disease. Pediatr Clin North Am. 1979;26:327–344.
- Zhang J, Yu KF. What’s the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1691.
- Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976;295:530–533.
- Friedman WF, Hirschklau MJ, Printz MP, et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976;295:526–529.
- Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343:674–681.
- Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr. 2002;161:202–207.
- Ahamed MF, Verma P, Lee S, et al. Predictors of successful closure of patent ductus arteriosus with indomethacin. J Perinatol. 2015;35:729–734.
- Boo NY, Mohd-Amin I, Bilkis AA, et al. Predictors of failed closure of patent ductus arteriosus with indomethacin. Singapore Med J. 2006;47:763–768.
- Shaffer CL, Gal P, Ransom JL, et al. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med. 2002;30:343–348.
- Weiss H, Cooper B, Brook M, et al. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr. 1995;127:466–471.
- Levin M, McCurnin D, Seidner SR, et al. Postnatal constriction, ATP depletion, and cell death in the mature and immature ductus arteriosus. Am J Physiol Regul Integr Comp Physiol. 2006;290:R359–R364.